Panax notoginseng (medicinal materials) growers-Panax notoginseng (medicinal materials) retailers-Panax notoginseng (medicinal materials) dealers-pharmaceutical factories (medicinal materials manufacturers)-(medicinal materials) consumers: If the demand of market consumers is 7,000 tons all the way to the original medicinal materials growers, then good growers have also planted about 7,000 tons of output, but since 2009, God has not cooperated with natural disasters such as drought to reduce production. At this time, drug retailers can't receive drugs, so they can only buy them at a higher price. However, when drug dealers see that the difference between the purchase price and the selling price is widening, they also join the market to raise the price. This is the reason why we can see the price soaring on the surface: the price of raw materials received by deeper pharmaceutical manufacturers has risen, OK, the management of the US Food and Drug Administration in China has strictly controlled the price of finished products in the market, and the profit of pharmaceutical manufacturers has lost, leading to production reduction. However, the market demand for finished drugs is still sufficient, so there is still room for improvement. During this period, the self-regulatory ability of China's regulatory authorities remains to be discussed. It is suggested that the drug price should be adjusted reasonably, the regulation policy should be changed from gambling to thinning, and the medicinal material growers should be guided to plant rationally, instead of blindly following the trend, a medicinal material exchange should be established, and the market should be improved by advanced trading means. Every emerging market will have a transition period. Since some investors are willing to participate in this transaction, organize training and study for everyone to participate. Not only can finance be used to make investors and participants involved in this cycle mutually beneficial!